The overall incidence of hepatitis induced by immunotherapies has been reportedly low ~2–15%, and CTLA4 inhibitors have been reported to be associated with more cases of immune-mediated hepatitis (IH) than PD1/PDL1 inhibitors (49). The gene discussed is CTLA4; the disease is hepatitis A virus infection.